Immune status of volunteers one year after administration of Japanese encephalitis vaccine produced in India
- PMID: 2559892
Immune status of volunteers one year after administration of Japanese encephalitis vaccine produced in India
Abstract
The immune status of 40 volunteers who received the full course of Japanese encephalitis (JE) vaccine a year earlier and 15 individuals who had received only a booster dose at the same time, was studied by estimating the level of persistence of protective antibody in the sera. All the sera showed persistence of 100 per cent seroconversion rate. Individuals who had the full course of vaccination still had high levels of antibody (mean 2.8 Iog10); however there was a fall of 0.8 Iog10 from the post-booster level. Volunteers who had received only a booster dose, also showed persistence of high level of protective antibody (mean 2.4 Iog10), a drop of 0.9 Iog10 from the post-booster level. Neutralizing (N) antibody estimated using Dibrugarh (7812474) strain of JE virus also demonstrated persistence of high level of protective antibody against this virus (mean 2.4 Iog10). Persistence of high level of protective antibody against homologus and heterologus (Dibrugarh) virus strains and absence of vaccine related side-effects even one year after administration of JE vaccine produced in India, demonstrates the immunizing potency and safety of this new vaccine.
Similar articles
-
Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India.Indian J Med Res. 1995 Dec;102:267-71. Indian J Med Res. 1995. PMID: 8557319 Clinical Trial.
-
Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.Vaccine. 2013 Dec 17;32(1):119-23. doi: 10.1016/j.vaccine.2013.10.055. Epub 2013 Oct 28. Vaccine. 2013. PMID: 24176496
-
Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.Vaccine. 2015 Jul 9;33(30):3600-4. doi: 10.1016/j.vaccine.2015.05.037. Epub 2015 May 30. Vaccine. 2015. PMID: 26036947
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.J Infect Dis. 2003 Oct 15;188(8):1213-30. doi: 10.1086/378356. Epub 2003 Oct 3. J Infect Dis. 2003. PMID: 14551893 Clinical Trial.
-
Neutralizing antibody responses to Japanese encephalitis vaccine in children.Biken J. 1983 Mar;26(1):25-34. Biken J. 1983. PMID: 6626137
Cited by
-
Control of Japanese encephalitis in India: a reality.Indian J Pediatr. 2004 Aug;71(8):707-12. doi: 10.1007/BF02730659. Indian J Pediatr. 2004. PMID: 15345871 Review.
-
Vaccines for preventing Japanese encephalitis.Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD004263. doi: 10.1002/14651858.CD004263.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636750 Free PMC article.